Gapping down
In reaction to disappointing earnings/guidance: JKS -9.1%, FRO -8%.
M&A news: PF -6.1% (still checking), AZN -1.7% (Pfizer issues statement regarding AstraZeneca (AZN); does not intend to make an offer for AstraZeneca, also downgraded to Sell from Hold at Societe Generale).
Select metals/mining stocks trading lower: GFI -3.3%, AU -3.1%, AU -3.1%, SLV -1.7%, GDX -1.4%, HMY -1.3%, GLD -1.2%, ABX -1.2%, AG -1.2%, SLW -1%, HL -1%, .
Select solar names showing early weakness in sympathy with JKS: CSIQ -2.8%, TSL -2.4%, YGE -1.5%.
Other news: DRTX -8.8% (confirms FDA approval of Dalvance, inititially traded higher, and sold off pre-mkt), BIOD -5.4% (discloses CFO resigned), CVM -3.8% (files for $75 mln mixed securities shelf offering), YY -1% (rumors of site clean-up operation by government, co denies rumors), .
Analyst comments: NTLS -2.1% (downgraded to Hold from Buy at Jefferies), SPLS -0.9% (downgraded to Sell from Neutral at Goldman).
In reaction to disappointing earnings/guidance: JKS -9.1%, FRO -8%.
M&A news: PF -6.1% (still checking), AZN -1.7% (Pfizer issues statement regarding AstraZeneca (AZN); does not intend to make an offer for AstraZeneca, also downgraded to Sell from Hold at Societe Generale).
Select metals/mining stocks trading lower: GFI -3.3%, AU -3.1%, AU -3.1%, SLV -1.7%, GDX -1.4%, HMY -1.3%, GLD -1.2%, ABX -1.2%, AG -1.2%, SLW -1%, HL -1%, .
Select solar names showing early weakness in sympathy with JKS: CSIQ -2.8%, TSL -2.4%, YGE -1.5%.
Other news: DRTX -8.8% (confirms FDA approval of Dalvance, inititially traded higher, and sold off pre-mkt), BIOD -5.4% (discloses CFO resigned), CVM -3.8% (files for $75 mln mixed securities shelf offering), YY -1% (rumors of site clean-up operation by government, co denies rumors), .
Analyst comments: NTLS -2.1% (downgraded to Hold from Buy at Jefferies), SPLS -0.9% (downgraded to Sell from Neutral at Goldman).